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Repairing damaged heart muscles: the challenges
Recent years have seen a significant rise in patient survival rate after myocardial infarction, 
commonly known as heart attack. This is mainly due to improvement in hospital instrument 
facilities, clinical management system, surgical tools and technologies. However, many of 
these patients soon develop heart failure, with 50% mortality rate within 5 years of heart 
attack [1]. As the regeneration power of the heart muscle is very limited, negative 
remodeling and nonfunctional scar tissue deposition leads to gradual terminal failure of the 
heart. Current treatments include heart transplantation and ventricular assist devices, which 
are both highly invasive and risky surgical procedures with inconsistent results. Stem cell 
transplantation has recently shown some potential that can improve heart function through 
several mechanisms such as cardiac differentiation, neoangiogenesis and paracrine effects 
[2]. Despite promising results, stem cell therapy still remains limited because of economic, 
timing and logistic issues, particularly when isolating cells from elderly patients under 
clinical settings. Reduced cell survival and retention at the transplant site further limits their 
therapeutic potential [3]. Thus, we see an urgent need for new strategies to attenuate the 
progression of the disease postmyocardial infarction. The following sections highlight the 
emerging roles of biocompatible nanomaterials and hydrogels and provide insights for 
further development in cardiac therapy and tissue engineering applications.
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Nanomaterials & injectable hydrogels: how they can help repair damaged 
cardiac tissues
Although still in its early stage of development, the field of nanomedicine for cardiovascular 
therapy has evolved rapidly over the years with new discoveries in nanomaterials science 
[4]. In particular, local intramyocardial delivery of therapeutic nanoparticles, including 
lipopolymers and viral nanocarriers, has shown impressive in vivo results to provide early 
cardioprotection and enhance neovascularization of injured tissue [5–8]. However, retention 
of the implanted nanotherapeutics at the target site for an optimal duration is critical for the 
success of the therapy. And this is particularly challenging when delivering therapeutics to 
cardiac environment where the wall of the heart is constantly beating driving substantial 
amount of cargo to other nonessential regions.
Injectable hydrogel that helps retain the nanotherapeutics at the target site may offer a viable 
solution to this problem. Compared to other procedures, hydrogel with compatible 
rheological properties aids in reducing the damage to the surrounding tissues along with the 
added capability to preserve the encapsulated drug at injected site. In general, therapeutic 
approaches of injectable hydrogels mainly include epicardial and endocardial injections. 
Main benefits of such delivery methods is that they allow direct access to the damaged tissue 
site, accurate placement and retention of the therapeutics compared with other methods. 
Injectable extracellular matrix (ECM) hydrogel from Ventrix Inc. (CA, USA), which is now 
going for clinical trial for myocardial therapy, is one such example [9]. Importantly, the 
liquid hydrogel precursor can be delivered in a single bolus or in multiple injection forms, 
where the later can subsequently get transitioned in situ into hydrogel state by shift in salt 
concentration, pH, temperature, or enzyme concentration. In case of bio-originated 
materials, such as decellularized ECM matrix, the hydrogel can additionally provide 
structural support and biochemical cues to the injured site which may induce endogenous 
stem cell homing for natural healing.
A smart selection of such drug carrying nanoparticles and injectable hydrogel can 
complement each other’s strengths and help develop the next generation therapeutics with 
multifunctional effects. Recently, it has been reported that DNA carrying nanomaterials in 
combination with naturally derived methacrylated gelatin (GelMA) hydrogel, can efficiently 
deliver DNA to the infarcted site when administered intramyocardially [10]. We also noticed 
that VEGF gene-activated nano graphene oxide (GO), suspended in injectable GelMA, can 
effectively deliver VEGF genes to the myocardial tissue in peri-infarct region which 
eventually leads to neovascularization, attenuation of cardiac dysfunction and scar 
formation. In fact GelMA alone, as a major ECM derivative, exhibit potential to induce 
functional benefits to the tissues because of its inherent biological cues. miRNA analysis of 
the tissues at injected site further confirmed the biocompatibility of the developed 
nanocomposite GelMA/GO hydrogel. Other studies have shown beneficial effects of 
injectable shear thinning hydrogels to deliver therapeutics to target site by its shear-induced 
flow properties commonly induced by syringes and catheters [11,12]. The shear-thinning 
materials recover back into hydrogel state immediately after delivery and retain the 
encapsulated therapeutics at the target site. Purcell et al., in an interesting study, 
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demonstrated that an on-demand matrix metalloproteinase (MMP) inhibition is possible 
using such injectable bioresponsive hydrogel which releases recombinant tissue inhibitors of 
MMPs only when MMP activity is increased postmyocardial infarction [13]. In recent years, 
several other bioresponsive materials for cardiac applications have been developed which, in 
combination with nanovectors, can deliver oxygen-releasing agents, small molecules, drugs 
and growth factors at injured site [14,15]. The technology can be further improved using 
nanoparticles which can bind to specific target sites. For this the nanoparticles must be 
surface functionalized with high density ligand molecules which can identify a substantially 
overexpressed molecular target at the injured tissue site. It is also important to mention here 
that these nanohybrids can be surgically implanted at any site in patients with minimal prior 
knowledge of the geometry of the injured site.
Engineering miniaturized cardiac tissues: role of biomimetic 
nanocomposite hydrogels
The last few years have seen significant thrust in designing in vitro miniaturized healthy and 
diseased cardiac tissue models also known as ‘heart on-a-chip’ [16,17]. To achieve this goal 
tissue engineering is now entering a new era where it merges the insights of microscale 
technologies with stem cell biology, in particular induced pluripotent stem cells. So far the 
cardiac and stem cell originated in vitro cardiac tissue prototypes have demonstrated that 
they can help better understand the cell–drug interactions, drug resistance and cytotoxicity, 
pharmacological profiling and instigate personalized medicine practice. Moreover, such 
bioengineered cardiac constructs can also be used as cardiac patches for functional tissue 
replacement therapy. However, one of the main challenges to develop such a clinically 
relevant tissue engineered cardiac structure is replicating the unique morphological, 
physiological and functional properties of the native myocardium.
In a classical approach, cardiac cells are combined with hydrogels, and cultivated in 
perfusable bioreactors which provide mechanical and electrical stimulation. Yet, poor 
conductive nature of commonly used biomaterials result in cardiac constructs with 
suboptimal performance. Incorporation of electroconductive nanomaterials such as carbon 
nanotubes (CNTs) and GO nanosheets can potentially solve this problem. CNT-reinforced 
hybrid GelMA hydrogel has been shown to improve mechanical and electrical properties of 
hydrogel [18]. The resulting nanocomposite hydrogel significantly improved cardiomyocyte 
alignment, maturation and electrophysiological functions. Developing such biomimetic 
nanocomposite hydrogels can facilitate proper electroconductive network and establish 
spontaneous beating behavior within the cardiac cells. Toward the same goal Dvir et al. 
demonstrated that the addition of gold nanowires and nanoparticles to biomaterial-based 
hydrogels can significantly enhance electrical communication between neighboring cardiac 
cells in a 3D microenvironment [19,20]. As a result, the adjacent cardiac cells exhibited a 
synchronous response to electrical pacing and generated proper excitation–contraction 
coupling with each beat. Thus it can be stated that the ability to fabricate functional cardiac 
tissues depends on engineering hydrogels which closely represents cardiac cell niche and 
biomimetic microarchitechture.
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It can be envisaged from the recent studies articulated in this editorial that nanohybrid 
hydrogels can be highly useful for cardiac tissue engineering and therapeutics. Although 
new nanocomposite biomaterials are consistently being developed, we need to prioritize 
these materials as per biomedical applications. Studies with generally-recognized-as-safe 
materials and hydrogels will have the greatest chances for clinical translation. However, 
several challenges need to overcome before considering them fit for clinical realization. This 
includes inventing methods to vascularize the engineered cardiac tissues, optimization of 
microfabrication technique to consistently develop identical cardiac constructs for high-
throughput screening and drug discovery applications. Other concerns related to application 
of nanocomposite injectable hydrogel include long-term biosafety of the implants, easy 
integrateability of hydrogel to host tissue and knowledge about fate of implanted 
nanomaterials postimplantation. While these are few of the many parameters that need to be 
investigated in designing nanocomposite hydrogels for specific cardiac applications, clearly 
many unique opportunities and challenges await equally for the clinicians and academic 
research communities. The demand for new class of clinical therapies for cardiovascular 
diseases is rapidly rising and these encouraging results offer a promising future.
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